Corcept Therapeutics Stock Earnings Reports

Corcept reported Q1 2026 revenue of $164.9M (up from $157.2M) and raised 2026 revenue guidance to $950M–$1.05B. Net loss was $31.8M in the quarter and cash & investments were $515M at March 31. The endocrinology business is showing record new prescriptions, prescribers and patient starts (March and April records), but revenue impact is partially delayed by annual payer reauthorizations, new-patient dosing/titration and prior-authorization backlogs after a specialty pharmacy transition. Landmark CATALYST and MOMENTUM studies demonstrated high rates of hypercortisolism in resistant diabetes (24%) and resistant hypertension (27%), respectively, which management expects will expand screening and materially grow the Cushing’s-related market (targeting at least $2B annual revenue for current Cushing’s medicines by decade-end). In oncology, the FDA approved Lifyorli for platinum-resistant ovarian cancer 3.5 months early; the pivotal ROSELLA trial met both primary endpoints with a 35% reduction in risk of death (HR 0.65, p=0.0004). Corcept launched Lifyorli with rapid uptake (prescriptions from >200 physicians within ~5 weeks) and NCCN preferred status; management targets >$1B U.S. annual revenue for Lifyorli by decade-end. Relacorilant’s NDA for Cushing’s syndrome recently had an FDA meeting; updates to come. Multiple development programs are underway: BELLA (relacorilant combinations) with first-arm readout by year-end, a Phase III expected to start in ALS based on DAZALS (300 mg showed large survival benefit at 1 and 2 years), MONARCH Phase IIb in MASH readout by year-end, and a nenocorilant Phase I studying combinations with immunotherapy. Company plans to expand specialty pharmacy network later this year to handle volume growth. Overall message: strong commercial momentum in endocrinology and an encouraging early oncology launch, with multiple high-impact pipeline programs that could meaningfully expand addressable markets.